Navigating ADCs and Other Treatment Options in Breast Cancer Care

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, explore how clinicians navigate antibody-drug conjugates (ADCs) alongside other available treatment options in breast cancer care. Natsuhara discusses the challenges of making treatment decisions in the absence of head-to-head data, often relying on cross-trial comparisons and clinical judgment. Iyengar underscores the importance of considering mechanism of action, toxicity profiles, and patient-specific factors when selecting among competing therapies.